How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,828 results for

Diphenhydramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

103. European Academy of Neurology guideline on the management of medication-overuse headache

- usual frequency during the initial withdrawal period without the fear of causing rebound MOH. The drugs proposed for the treatment of headache dur- ing withdrawal as a bridging therapy are those rec- ommended for the acute migraine attack, e.g. diphenhydramine [93], dihydroergotamine [94], anti- dopaminergic drugs (chlorpromazine, prochlorper- azine, metoclopramide, droperidol) [95-98], valproic acid [99], ketorolac [10], magnesium [11] or corticos- teroids [12,103]. Many medications have been

2020 European Academy of Neurology

104. Transfusion reaction

-associated sepsis, and circulatory overload, should be considered in the differential diagnosis. Acute haemolytic transfusion reactions are most often the result of clerical error. Identification is critical because of the high probability of a second patient receiving the wrong blood product at the same time. Treatment depends upon the type of transfusion reaction. Although pretransfusion prophylactic paracetamol and diphenhydramine are often routinely administered, there is little evidence to support

2018 BMJ Best Practice

105. Pharmacological management of migraine

for complete headache relief when compared to metoclopramide. 29 Both prochlorperazine 10 mg and metoclopramide 20 mg (both coadministered with diphenhydramine and given intravenously) were found to be effective for pain relief at one hour for patients with acute migraine, as recorded on the NRS scale. At two hours the NRS for pain after treatment with prochlorperazine was 6.4 from a baseline NRS of 8.4, and for metoclopramide 5.9 from a baseline NRS of 8.8. The overall difference was 0.6 (95% CI -0.6

2018 SIGN

106. Atezolizumab (non-small cell lung cancer) ? Benefit assessment according to §35a Social Code Book V

ibuprofen), diphenhydramine and/or cimetidine, or other H2 receptor antagonists ? after cycle 1, day 14 radiotherapy for alleviation of pain Docetaxel arm: ? granulocyte-stimulating medications ? antiemetics, antiallergics if approved by the investigator Atezolizumab arm: ? = cycle 2 systemic corticosteroids, TNFa inhibitors; epinephrine, antihistamines for the treatment of AEs Non-permitted concomitant treatment: Docetaxel: ? CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin (...) of the interventions – RCT, direct comparison: atezolizumab vs. docetaxel (continued) Concomitant treatment: Concomitant treatment permitted: ? analgesics at a stable dosage at the start of the study ? antipyretics (preferably ibuprofen), diphenhydramine and/or cimetidine, or other H2 receptor antagonists ? megestrol to stimulate appetite ? oral contraceptives, hormone replacement therapy, prophylactic or therapeutic anticoagulants (e.g. low molecular weight heparin or warfarin) at a stable dose ? after cycle 1

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

107. Axicabtagene ciloleucel (Yescarta) - diffuse large B-cell lymphoma (DLBCL); primary mediastinal large B-cell lymphoma (PMBCL)

and fludarabine 30 mg/m 2 intravenous should be administered on the 5th, 4th, and 3rd day before infusion of YESCARTA. Pre-medication • Paracetamol 500-1000 mg given orally and diphenhydramine 12.5 mg intravenous or oral (or equivalent) approximately 1 hour before YESCARTA infusion is recommended. • Prophylactic use of systemic steroids is not recommended as it may interfere with the activity of YESCARTA. Monitoring • Patients should be monitored daily for the first 10 days following infusion for signs

2018 European Medicines Agency - EPARs

109. Methocarbamol

of diphenhydramine, lorazepam and methocarbamol : evaluation of abuse liability. 1501118 1992 09 11 1992 09 11 2015 11 19 0022-3565 262 2 1992 Aug The Journal of pharmacology and experimental therapeutics J. Pharmacol. Exp. Ther. Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol : evaluation of abuse liability. 707-20 The effects of orally administered placebo, diphenhydramine, lorazepam, methocarbamol and placebo were studied (...) in volunteers with histories of recreational (...) substance abuse including sedative/hypnotics. Placebo, diphenhydramine (100, 200 and 400 mg), lorazepam (1 and 4 mg) and methocarbamol (2.25 and 9 g) were tested in a randomized, double-blind crossover study using 14 subjects. Psychomotor and cognitive performance and subject- and observer-rated responses were measured daily before and for 5.5 hr after drug administration. The results showed that each of the drugs exhibited a different profile of effects 1992 Follow us: © 2019 Trip Database Ltd. company

2018 Trip Latest and Greatest

110. Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Acute Headache

Class II 33-35 and 10 Class 388 III 36-45 studies. 389 In a Class II study published by Friedman et al, 33 the authors compared outcomes among ED patients with 390 migraine who received intravenous hydromorphone versus those who received intravenous prochlorperazine and 391 diphenhydramine. This was a double-blinded study that was halted by the data monitoring committee after 392 enrollment of 127 patients because of clear benefit in the nonopioid arm of the study. The primary outcome 393 included

2019 American College of Emergency Physicians

111. Axicabtagene ciloleucel (Yescarta) - relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL)

, and third day before infusion of axicabtagene ciloleucel. Pre-medication: Paracetamol 500mg to 1,000mg given orally and diphenhydramine 12.5mg intravenous or oral (or equivalent) approximately one hour before axicabtagene ciloleucel infusion is recommended. Axicabtagene ciloleucel must be administered in a qualified clinical setting. Axicabtagene ciloleucel should be initiated under the direction of and supervised by a healthcare professional experienced in the treatment of haematological malignancies

2019 Scottish Medicines Consortium

113. Tisagenlecleucel (Kymriah) - diffuse large B-cell lymphoma (DLBCL)

be pre- medicated with paracetamol and diphenhydramine (or another H1 antihistamine) approximately 30 to 60 minutes before tisagenlecleucel infusion. Tisagenlecleucel must be administered in a qualified treatment centre, and should be initiated under the direction of and supervised by a healthcare professional experienced in the treatment of haematological malignancies and trained for administration and management of patients treated with tisagenlecleucel. A minimum of four doses of tocilizumab (...) was a single intravenous infusion of 5.0 × 10 8 viable tisagenlecleucel transduced cells (acceptable dose range was 1.0 to 5.0 x 10 8 viable tisagenlecleucel transduced cells). Patients were given premedication with paracetamol and diphenhydramine or another H1 antihistamine every six hours as needed. 2 The primary outcome was overall response rate (ORR), defined as a best overall response of complete or partial response until progressive disease or start of new anticancer therapy. Response was assessed

2019 Scottish Medicines Consortium

117. Tisagenlecleucel (Kymriah) - treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL)

(500mg/m 2 intravenously for two days starting with the first dose of fludarabine). It is recommended that tisagenlecleucel is infused two to 14 days after completion of the lymphodepleting chemotherapy. The availability of tisagenlecleucel must be confirmed prior to starting the lymphodepleting regimen. To minimise potential acute infusion reactions, it is recommended that patients be pre- medicated with paracetamol and diphenhydramine (or another H1 antihistamine) approximately 30 to 60 minutes (...) ). A single 5 intravenous infusion of tisagenlecleucel was given at the maximum dose within the range that could be manufactured: target dose range of 2.0 to 5.0×10 6 tisagenlecleucel cells per kg body weight for patients =50 kg and of 1.0 to 2.5×10 8 tisagenlecleucel cells per kg for patients >50 kg. Patients were given premedication with paracetamol and diphenhydramine or an H1 antihistamine every six hours as needed. 2 Of the 92 patients enrolled, 75 received tisagenlecleucel. The reasons

2019 Scottish Medicines Consortium

118. Axicabtagene ciloleucel (Yescarta) - Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL)

intravenous and fludarabine 30mg/m 2 intravenous should be administered on the fifth, fourth, and third day before infusion of axicabtagene ciloleucel. Pre-medication: Paracetamol 500mg to 1,000mg given orally and diphenhydramine 12.5mg intravenous or oral (or equivalent) approximately one hour before axicabtagene ciloleucel infusion is recommended. Axicabtagene ciloleucel must be administered in a qualified clinical setting. Axicabtagene ciloleucel should be initiated under the direction

2019 Scottish Medicines Consortium

119. Tisagenlecleucel (Kymriah) - for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

to starting the lymphodepleting regimen. To minimise potential acute infusion reactions, it is recommended that patients be pre- medicated with paracetamol and diphenhydramine (or another H1 antihistamine) approximately 30 to 60 minutes before tisagenlecleucel infusion. Tisagenlecleucel must be administered in a qualified treatment centre, and should be initiated under the direction of and supervised by a healthcare professional experienced in the treatment of haematological malignancies and trained (...) was a single intravenous infusion of 5.0 × 10 8 viable tisagenlecleucel transduced cells (acceptable dose range was 1.0 to 5.0 x 10 8 viable tisagenlecleucel transduced cells). Patients were given premedication with paracetamol and diphenhydramine or another H1 antihistamine every six hours as needed. 2 The primary outcome was overall response rate (ORR), defined as a best overall response of complete or partial response until progressive disease or start of new anticancer therapy. Response was assessed

2019 Scottish Medicines Consortium

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>